At a glance
- What the study gets you
- Access to the study treatment being tested
- Type of study
- Interventional (receives a drug or procedure)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Dalteparin Sodium (drug), Tinzaparin Sodium (drug), Enoxaparin Sodium (drug), Rivaroxaban (drug)
- How long the study runs
- Study runs about 47 months (dates as stated)
- About the drug or intervention
- Dalteparin Sodium — drug: Low molecular weight heparin · Tinzaparin Sodium — drug: Low molecular weight heparin · Enoxaparin Sodium — drug: Low molecular weight heparin · Rivaroxaban — drug: Direct oral anticoagulant · Apixaban — drug: Direct oral anticoagulant · Dabigatran Etexilate — drug: Direct oral anticoagulant
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Testing a treatment
- Ages
- 18 Years and over
- Who
- All
- Number of participants
- 3,175
- Started
- 2024-01-22
- Last checked
- 2026-06
Plain English Summary
What is this study?
- • Testing a new treatment for venous thromboembolism
- • Phase4 - 3,175 participants
- • Endovenous interventions are keyhole operations for varicose veins that are carried out from within the vein itself
Who can take part?
- • Ages 18 Years and over
- • Diagnosed with venous thromboembolism
Where?
- • London - Imperial College Hospital NHS Foundation Trust
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
Endovenous interventions are keyhole operations for varicose veins that are carried out from within the vein itself. Varicose veins are enlarged veins close to the surface of the skin. They are connected to the bigger deeper veins in the leg (known as deep veins). Because of this, operations to close the varicose veins can increase the chance of a blood clot forming in the deep veins. Blood clots in the deep veins happen in around 1 in 50 people after endovenous operations. A clot in the leg can cause swelling, pain, and other long-term problems. If a clot in the leg breaks off and travels to the lungs, it can cause problems with the lung' ability to move oxygen from the air into the blood and may, in rare cases, be life threatening. Varicose vein procedures may carry a slightly higher risk of blood clot formation, and we are currently unsure if current clot reducing medicines are beneficial in preventing blood clots in people having varicose vein procedures. This study will investigate if it is worthwhile prescribing medicines to reduce blood clots after varicose vein procedures.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years and over
- Who can join: All genders
Biomarkers mentioned
What the study is looking for
- ✓Adults (\>18 years)
- ✓Scheduled to undergo endovenous intervention of truncal varicose veins under local anaesthesia
- ✓Treatment technologies including radiofrequency, laser, mechanochemical, foam sclerotherapy and cyanoacrylate glue
Who cannot take part
- ✗Clinical indication for therapeutic anticoagulation e.g., atrial fibrillation
- ✗Previous personal or first-degree relative history of VTE
- ✗Thrombophilia
- ✗Female patients of childbearing potential who have a positive pregnancy test
- ✗A history of allergy to heparins or direct oral anticoagulants
See the full criteria
Where Is This Study? (1 UK site)
Imperial College Hospital NHS Foundation Trust
London W6 8RF, United Kingdom
How to Get in Touch
Sarah Whittley
Sponsor contactCONTACT